natgillin/translations-raw huggingface dataset:
5.1 for detaljer om forsøget) svarede antallet af alvorlige kardiovaskulære hændelser (MACE) for febuxostat til det for patienter behandlet med allopurinol (HR 1,03; 95 % CI: 0,87-1,23), men der blev observeret et højere antal kardiovaskulære dødsfald (4,3% vs. 3,2 % af patienterne; HR 1,34; 95 % CI: 1,03-1,73). 
In the post registrational CARES trial (see section 5.1 for detailed characteristics of the study) the rate of MACE events was similar in febuxostat versus allopurinol treated patients (HR 1.03; 95% CI 0.871.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73).
Hvis De snart skal tage den næste dosis, så spring den glemte dosis over. 
If you miss a dose of ADENURIC take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time.
APEX-studiet: I løbet af de 8 ugers profylaktisk behandling måtte en større andel af deltagerne i behandlingsgruppen, der fik febuxostat 120 mg (36 %), behandles for udbrud af arthritis urica sammenlignet med grupperne, der fik febuxostat 80 mg (28 %), allopurinol 300 mg (23 %) eller placebo (20 %). 
Apex study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%).
I CONFIRMS-studiet var andelen af patienter med serumuratniveau ved baseline på ≥ 595 µmol/l (10 mg/dl), der opnåede det primære effektmål (serumurat < 357 µmol/l (6,0 mg/dl) ved det sidste besøg), 27 % (66/249) ved behandling med febuxostat 40 mg en gang dagligt, 49 % (125/254) med febuxostat 80 mg en gang dagligt og 31 % (72/230) med allopurinol 300 mg/200 mg en gang dagligt. 
6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.
Cirka 40 % af patienterne (kombineret APEX og FACT) havde et serumurinsyreniveau ved baseline på ≥ 595 µmol/l (10 mg/dl). 
Primary endpoint in the sub group of patients with sUA ≥ 10 mg/dL Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of ≥ 10 mg/dL.
• svimmelhed, følelsesløshed, prikkende fornemmelse, nedsat eller ændret følefornemmelse 
• dizziness, numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia)
Efter markedsføringen er der forekommet sjældne tilfælde af alvorlige overfølsomhedsreaktioner på febuxostat inklusive Stevens-Johnsons syndrom, toksisk epidermal nekrolyse og anafylaksi/shock. 
Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience.
ADENURIC 120 mg tabletter Febuxostatum2. 
ADENURIC 120 mg tablets Febuxostat
Tabletten har kun delekærv for at muliggøre deling af tabletten, så den er nemmere at sluge. 
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Forhøjet blodglucose, forlænget aktiveret partiel tromboplastintid, nedsat erytrocyttal, forhøjet basisk fosfatase, forhøjet kreatinfosfokinase i blodet* * Bivirkninger rapporteret efter markedsføringen. 
Blood glucose increased, activated partial thromboplastin time prolonged, red blood cell count decrease, blood alkaline phosphatase increase, blood creatine phosphokinase increase* * Adverse reactions coming from post-marketing experience ** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.
FACT-studiet: I løbet af de 8 uger med profylaktisk behandling måtte en større andel af deltagerne i behandlingsgruppen, der fik febuxostat 120 mg (36 %), behandles for et udbrud af arthritis urica, sammenlignet med grupperne, der fik febuxostat 80 mg (22 %) eller allopurinol 300 mg (21 %). 
FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups.
Sådan skal De tage ADENURIC 
How to take ADENURIC
Luftveje 
Febuxostat
Kontakt lægen, før De tager denne medicin, hvis lægen har fortalt Dem, at De ikke tåler visse sukkerarter. 
If you have been told that you have an intolerance to some sugars contact your doctor before taking this medicine.
ADENURIC 80 mg tabletter Febuxostatum2. 
ADENURIC 80 mg tablets Febuxostat
• rødme af huden (erytem), forskellige former for udslæt (f.eks. kløende, med hvide pletter, med blærer, med betændte blærer, med afskalning eller mæslingelignende), udbredt rødme af huden, 
• reddening of the skin (erythema), rash in various types (e.g. itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (Stevens-Johnson Syndrome/Toxic epidermal necrolysis)
ADENURIC 120 mg filmovertrukne tabletter Febuxostatum2. 
ADENURIC 120 mg film-coated tablets Febuxostat
patienter med serumkreatinin >90 µmol/l (1,5 mg/dl) og 119 µmol/l (2,0 mg/dl)) eller 300 mg en gang dagligt (n=509) var poolet til analyserne. 
1 results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine >1.5 and ≤2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses.
ADENURIC 120 mg ADENURIC 240 mg 
ADENURIC 240 mg
LÆGEMIDLETS NAVN ADENURIC 80 mg filmovertrukne tabletter 
ADENURIC 80 mg film-coated tablets
LÆGEMIDLETS NAVN ADENURIC 120 mg filmovertrukne tabletter 
ADENURIC 120 mg film-coated tablets
ADENURIC 80 mg filmovertrukne tabletter Febuxostatum2. 
ADENURIC 80 mg film-coated tablets Febuxostat
Der er i forbindelse med brug af ADENURIC i sjældne tilfælde indberettet udslæt, som kan være livstruende (Stevens-Johnsons syndrom). 
There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of ADENURIC, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk.
ADENURIC 80 mg filmovertrukne tabletter ADENURIC 120 mg filmovertrukne tabletter Febuxostat 
Package leaflet: Information for the user ADENURIC 80 mg film-coated tablets ADENURIC 120 mg film-coated tablets
alopeci hyperhidrose 
Hepato-biliary disorders
Almindelige Leverfunktionsforstyrrelser** 
Liver function abnormalities** Uncommon
Primært endepunkt i undergruppen af patienter med serumurinsyre ≥ 595 µmol/l (10 mg/dl) 
Table 2 Proportion of Patients with Serum Uric Acid Levels <6.0 mg/dL (357 µmol/L)
Patienten skal monitoreres og behandles på passende vis. 
The patient should be monitored and treated appropriately.
Vægtstyring og yderligere risikofaktorer 
Weight management and additional risk factors
- De anbefales at dele oplysningerne i denne indlægsseddel med pårørende eller andre relevante personer. 
- You are advised to share the information in this leaflet with relatives or other relevant persons.
Der er ingen tilstrækkelige eller velkontrollerede forsøg med gravide. 
There are no adequate or well-controlled studies in pregnant women.
Effekt af mad: 
Effect of food:
Et opdateret risk management plan, skal forefindes som beskrevet i CHMP guideline on risk management systems for medicinal products for human use. 
An updated risk management plan should be provided as per the CHMP guideline on risk management systems for medicinal products for human use.
ACOMPLIA er ikke anbefalet til brug hos børn under 18 år p.g.a. mangel på data vedrørende effekt og sikkerhed. 
ACOMPLIA is not recommended for use in children below age 18 due to a lack of data on efficacy and safety.
Forskel (CI 95 %) 
Difference (CI 95%)
ACOMPLIA til personer under 18 år 
in people under 18 years of age.
I alt blev mere end 6800 patienter inkluderet i fase 2 og fase 3 kliniske forsøg. 
In total more than 6800 patients were included in the Phase 2 and Phase 3 clinical studies.
Patienter bør instrueres i ikke at forøge dosis af ACOMPLIA. 
Patients should be instructed not to increase their dose of ACOMPLIA.
Tegn og symptomer i forbindelse med depression kan være: 
Signs and symptoms associated with depression could be:
Den potentielle relevans af dette i forhold til administration af CB1 antagonister er ukendt. 
The potential relevance of this to administration of a CB1 antagonist is unknown.
Cirka 80 % af populationen var kvinder, 87 % kaukasier og 9 % negroide. 
Approximately 80% of the population were women, 87% Caucasian and 9% Black.
Vægt ved baseline (kg) 
Weight at baseline (kg)
Selvom maternal toksicitet blev observeret ved disse doser, kan en relation til behandlingen ikke udelukkes. 
Although maternal toxicity was observed at these doses, a relation to treatment cannot be excluded.
Det anbefales at monitorere blodsukkerniveauet hos disse patienter. 
Monitoring of blood glucose level is recommended in these patients.
Steady state rimonabant eksponering er 3,3 gange højere end det observerede efter første dosis. 
Steady state rimonabant exposures are 3.3-fold higher than those observed after the first dose.
Effekten på kropsvægt synes at være den samme for mænd og kvinder. 
The effects on body weight appeared to be consistent among men and women.
Ændringer i HDL-C og TG i denne population svarede til dem i ikke-diabetespopulationen. 
Changes in HDL-C and TG in this population were similar to that of the non-diabetic population.
INFORMATION I BRAILLE-SKRIFT ACOMPLIA 
INFORMATION IN BRAILLE ACOMPLIA
ACOMPLIA 20 mg havde generelt ingen signifikant effekt på Total-C eller LDL-C niveauer. 
Generally ACOMPLIA 20 mg had no significant effect on Total-C or LDL-C levels.
Tabel 1: Organ-klasse system Meget almindelig Almindelig 
Table 1: System Organ Class
Fedme er en tilstand, som kan associeres med depressive sygdomme. 
Obesity is a condition that can be associated with depressive disorders.
Deres læge bør anbefale typen af diæt og den fysiske aktivitet, som passer til Deres specifikke kondition og helbred. 
Your doctor should recommend the type of diet and the level of physical activity required, that suits your specific condition and overall health.
Det meste af den observerede vægtreduktion blev set inden for de første 9 måneders behandling. 
Most of the observed weight reduction was obtained within the first nine months of treatment.
ACOMPLIA bør ikke anvendes under graviditet. 
ACOMPLIA should not be taken during pregnancy.
Klassifikation af forventede frekvenser af bivirkninger: 
Classification of expected frequencies of undesirable effects:
Anvendelse under graviditet anbefales derfor ikke. 
Use in pregnancy is, therefore, not recommended.
En proconvulsant aktivitet af rimonabant blev fundet i et ud af to safety farmakologiforsøg. 
A proconvulsant activity of rimonabant was found in one of two safety pharmacology studies.
Forskellen i halveringstiden skyldtes forskellen i det perifere distributionsvolume som konsekvens af lavere vægt hos japanske personer. 
The difference in half-life was due to differences in peripheral volume of distribution as a consequence of lower weight in Japanese subjects.
I nogle men ikke alle tilfælde synes initieringen af kramper at være associeret med stress under proceduren, såsom håndtering af dyrene. 
In some, but not all cases, initiation of convulsions appeared to be associated with procedural stress such as handling of the animals.
Patienterne inkluderet i fase 3 forsøgene fulgte en restriktiv diæt under forsøget ordineret af en diætist og de blev rådet til at forøge deres fysiske aktivitet. 
The patients included in the phase 3 trials followed a restrictive diet during the trial prescribed by a dietician and they were advised to increase their physical activity.
Meget almindelig (≥ 10 %); Almindelig (≥ 1, < 10 %); Usædvanlig (≥ 0,1, < 1 %); Sjælden (≥ 0,01, < 0,1 %); Meget sjælden (< 0,01 %), ikke kendt (kan ikke estimeres ud fra de forhåndenværende data). 
Very common (≥10%); Common (≥1, <10%); Uncommon (≥0.1, <1%); Rare (≥0.01, <0.1%); Very rare (<0.01%), Not known (cannot be estimated from the available data).
Erfaring med patienter over 75 år og orientalere/asiater er begrænset. 
Experience in patients over 75 years and Orientals/Asians was limited.
Der er ingen information tilgængelig vedrørende anvendelse af 
There is no information available on the use of ACOMPLIA
In vitro human plasmaproteinbinding af rimonabant er høj (> 99,9 %) og ikke-mættet over et stort koncentrationsområde. 
The in vitro human plasma protein binding of rimonabant is high (> 99.9%) and non-saturable over a wide concentration range.
Patienter bør informere deres læge, hvis de bliver gravide under behandling med ACOMPLIA. 
Patients should notify their physician if they become pregnant during treatment with ACOMPLIA.
Behandlingen bør introduceres med en lettere reduceret kaloriediæt. 
The treatment should be introduced with a mildly reduced calorie diet.
Disse inkluderede hovedpine, eufori, træthed og insomnia. 
These included headache, euphoria, fatigue and insomnia.
Der kan ikke drages nogle konklusioner vedrørende effekt for patienter over 75 år eller for asiater/orientalere p.g.a. af det lave antal patienter. 
No conclusions can be drawn with regard to effects in patients over 75 years or in Asian/Oriental patients due to the low number of patients.
Ældre patienter har lidt højere optagelse end unge patienter. 
Elderly patients have slightly higher exposure than young patients.
Det vides ikke, om rimonabant udskilles i human mælk. 
It is not known if rimonabant is excreted in human milk.
Depressive tilstande kan forekomme hos patienter, som ikke har nogen åbenlyse risikofaktorer, bortset fra fedme. 
Depressive reactions may occur in patients who have no obvious risk factors, apart from obesity itself.
De bør konsultere Deres læge eller apotek, hvis De er usikker. 
You should check with your doctor or pharmacist if you are not sure.
Negroide patienter kan have op til 31 % lavere Cmax og 43 % lavere AUC end patienter af anden race. 
Black patients may have up to a 31% lower Cmax and a 43% lower AUC than patients of other races.
Rimonabant 20 mg reducerede risikoen for vægtforøgelse. 
Rimonabant 20 mg reduced the risk of weight regain.
Der blev ikke observeret kramper hos hunde under et 3 måneders forsøg. 
No convulsions were observed in dogs during a 3 month study.
Tiden til steady state er længere hos obese patienter (25 dage) som en konsekvens af det højere distributionsvolumen i disse patienter. 
Time to steady state is longer in obese patients (25 days) as a consequence of the higher volume of distribution in these patients.
Cirkulerende metabolitter bidrager ikke til den farmakologiske aktivitet. 
Circulating metabolites do not contribute to its pharmacologic activity.
ACOMPLIAS VIRKNING, OG HVAD DE SKAL BRUGE DET TIL 
WHAT ACOMPLIA IS AND WHAT IT IS USED FOR
4.3 og 4.8). 
(See section 4.3 and 4.8).
UDLØBSDATO EXP {MM/YYYY} 
EXPIRY DATE EXP {MM/YYYY}
Kontakt straks Deres læge hvis De bliver gravid, hvis De har formodning om, at De er gravid eller planlægger at blive gravid, mens De anvender ACOMPLIA. 
Contact your doctor immediately if you become pregnant, think you might be pregnant or are planning to become pregnant while taking ACOMPLIA.
Eksisterende major depressiv sygdom og/eller igangværende antidepressiv behandling (se pkt. 
Ongoing major depressive illness and/or ongoing antidepressive treatment (see section 4.4)
I obese patienter er eliminationshalveringstiden længere (ca.16 dage) end i ikke-obese patienter (ca. 9 dage) p.g.a. af et højere distributionsvolume. 
In obese patients, the elimination half-life is longer (about 16 days) than in non-obese patients (about 9 days) due to a larger volume of distribution.
Baseret på farmakokinetiske populationsanalyser (alder fra 18-81 år), er en 75-årig patient estimeret til at have en 21 % højere Cmax og en 27 % højere AUC end en 40-årig patient. 
Based on a population pharmacokinetic analysis (age range 18 - 81 years) a 75 year old patient is estimated to have a 21% higher Cmax and a 27% higher AUC than a 40 year old patient.
Det tilsyneladende perifere distributionsvolume for rimonabant synes at være relateret til kropsvægt, hvor obese patienter har et højere distributionsvolume end personer med normal vægt. 
The apparent peripheral volume of distribution of rimonabant appears to be related to body weight, with obese patients having a higher volume of distribution than normal-weight subjects.
Som vægten forøges fra 65 kg til 200 kg, forventes Cmax at falde 24 % og Cmin forventes at forøges med 5 %. 
As weight increases from 65 to 200 kg, Cmax is expected to decrease 24% and Ctrough is expected to increase by 5%.
Sikkerhed og effekt af rimonabant er ikke undersøgt ud over 2 år. 
The safety and efficacy of rimonabant have not been evaluated beyond 2 years.
Erfaring efter markedsføring viser at mere en halvdelen af de patienter, som får disse reaktioner, får dem inden for en måned efter start af behandling, mere end 80% inden for de 3 første måneder. 
In postmarketing experience, more than half of the patients who develop such reactions appear to do so within 1 month of starting treatment, approximately 80% appear to do so within 3 months.
Hvis De oplever depressive symptomer (se nedenfor) under behandling med ACOMPLIA, bør De kontakte Deres læge og stoppe behandlingen. 
If you experience symptoms of depression (see below) during treatment with ACOMPLIA you should contact your doctor and stop the treatment.
Farmakoterapeutisk klassifikation: Antiobesitas middel ATC-kode: A08AX01 
Pharmaco-therapeutic group: Anti obesity agent ATC code: A08AX01
Patienter, især dem med depressive sygdomme/humør ændringer i anamnesen, (og pårørende eller andre relevante personer) bør gøres opmærksom på, at det er nødvendigt at monitorere forekomsten af sådanne symptomer og at søge læge øjeblikkeligt, hvis de skulle forekomme. 
Patients, especially those with a history of depressive disorders/mood alterations, (and relatives or other relevant persons) should be alerted about the need to monitor for the emergence of such symptoms and to seek medical advice immediately if these occur.
Vægtstyring 
Weight Management
Kun omkring 3 % af rimonabant-dosis bliver elimineret via urinen, mens omkring 86 % af dosis udskilles i fæces som uomdannet stof og metabolitter. 
Only an approximate 3% of the dose of rimonabant is eliminated in the urine, while approximately 86% of the dose is excreted in the faeces as unchanged drug and metabolites.
Hvordan man anvender ACOMPLIA sammen med mad og drikkevarer ACOMPLIA bør tages en gang dagligt om morgenen før morgenmaden. 
Taking ACOMPLIA with food and drink ACOMPLIA should be taken once daily in the morning before breakfast.
Bivirkninger, som ikke blev observeret i kliniske forsøg, men som blev set i dyr ved udsættelse for niveauer svarende til kliniske niveauer og med mulig relevans for klinisk brug, var som følger: 
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:
Procentdelen af patienter, som opnåede HbA1c < 7 ,% var 51 % i rimonabant-gruppen og 35 % i placebo-gruppen. 
The percentage of patients reaching HbA1c < 7% was 51% in the rimonabant group and 35% in the placebo group.
Begrænsede data antyder en forøget optagelse hos patienter med moderat nedsat nyrefunktion (40 % forøgelse i AUC). 
Limited data suggest an increased exposure in patients with moderate renal impairment (40% increase in AUC).
Depressive sygdomme kan associeres med en øget risiko for at gøre skade på sig selv, selvmordstanker og selvmord. 
Depressive disorders can be associated with an increased risk of suicidal thoughts, self harm and suicide.
Vigtig information om nogle af de øvrige indholdsstoffer i ACOMPLIA ACOMPLIA indeholder laktose. 
Important information about some of the ingredients of ACOMPLIA ACOMPLIA tablets include lactose.
Tag tabletten så snart De husker det, men De må ikke tage en dobbeltdosis som erstatning for en glemt tablet. 
If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose.
Slaphed/træthed Influenza 
Asthenia/fatigue Influenza
Administration af rimonabant til sunde fastende personer eller med et meget fedt måltid, viste at Cmax og AUC forøgedes henholdsvis 67 % og 48 % ved fedt måltid. 
Administration of rimonabant to healthy subjects in the fasted state or with a high fat meal demonstrated that Cmax and AUC were increased 67% and 48% respectively, under fed conditions.
De bør informere Deres læge, hvis nogen af ovenstående symptomer opstår, eller bliver værre efter behandlingen ar startet. 
You should inform your doctor if any of the symptoms listed above develop or worsen after treatment has begun.
Indehaver af markedsføringstilladelsen skal sikre at pharmacovigilancesystemet er til stde og fungerer før produktet markedføres. 
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market.
Effekt og sikkerhed af rimonabant hos patienter over 75 år er ikke tilstrækkeligt fastsat. 
The efficacy and safety of rimonabant treatment in patients over 75 years of age has not sufficiently been established.
Behandling med rimonabant var associeret med en signifikant reduktion i livsmål, en kendt markør for intra-abdominalt fedt. 
Treatment with rimonabant was associated with significant reductions in waist circumference, a known marker of intra-abdominal fat.
• Andre psykiatriske tilstande 
• Other psychiatric conditions
Effekten af rimonabant på præ- og postnatal udvikling blev undersøgt i rotter i doser op til 10 mg/kg/dag. 
Effects of rimonabant on pre- and post-natal development were assessed in the rat at doses up to 10 mg/kg/day.
* frekvens er kun baseret på rapporter på obese eller overvægtige personer. 
Joint sprain *frequency is based only on reports in obese or overweight diabetic patients.
I kliniske forsøg for andre indikationer, blev følgende, yderligere bivirkninger rapporteret som almindelige: 
In clinical studies for other indications, the following additional adverse reactions were commonly reported:
Potentiale for rimonabant for påvirkning af andre lægemidler: 
Potential for rimonabant to affect other medicinal products:
I enkelt- og gentagen-dosisforsøg var Cmax og AUC for rimonabant ens hos sunde japanske og kaukasiske personer, men eliminationshalveringstiden var kortere hos japanske personer (3-4 dage) sammenlignet med kaukasiske personer (ca. 9 dage). 
In single- and repeat-dose studies, the Cmax and AUC of rimonabant were similar in healthy Japanese and Caucasian subjects, whereas elimination half-life was shorter in Japanese subjects (3-4 days) compared to Caucasian subjects (about 9 days).
ACOMPLIA 20 mg var effektiv til at vedligeholde vægttab i op til 2 år. 
ACOMPLIA 20 mg was effective in maintaining weight loss up to two years.
Behandling bør bestå af generelle principper anvendt ved behandling af overdosis, såsom at holde luftvejene fri, monitorering af kardiovaskulær funktion og generelle og supportive målinger. 
Treatment should consist of the general measures employed in the management of overdoses, such as keeping airways unobstructed, monitoring cardiovascular function and general symptomatic and supportive measures.
Potentialet for hæmning af CYP2C8 in vivo synes at være lavt. 
The potential for inhibition of CYP2C8 in vivo appears to be low.
Patienter, der fik ACOMPLIA 20 mg, blev re-randomiseret til at få ACOMPLIA 20 mg eller placebo. 
Patients who received ACOMPLIA 20 mg for one year were re-randomized to ACOMPLIA 20 mg or placebo.
Tabel 2 
Table 2:
Køn: Rimonabants farmakokinetik er ens i kvindelige og mandlige patienter. 
Gender: The pharmacokinetics of rimonabant are similar in female and male patients.